Cambridge Enterprise has licensed key technology to Qkine, a spinout that is working on proteins to control stem cell growth.
Qkine, a UK-based stem cell technology developer spun out from University of Cambridge, signed a key licensing agreement with the institution’s tech transfer office Cambridge Enterprise on Tuesday.
The deal relates to Activin A production technology. Activin A, and related proteins, is one of the crucial elements in mimicking the environment in the human body and helps turn stem cells into specific cell types.
The technology was developed by co-founder Marko Hyvönen from the Department of Biochemistry.
Qkine was incorporated…
